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Brain activity patterns in high-throughput
electrophysiology screen predict both drug
efﬁcacies and side effects
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Neurological drugs are often associated with serious side effects, yet drug screens typically
focus only on efﬁcacy. We demonstrate a novel paradigm utilizing high-throughput in vivo
electrophysiology and brain activity patterns (BAPs). A platform with high sensitivity records
local ﬁeld potentials (LFPs) simultaneously from many zebraﬁsh larvae over extended peri-
ods. We show that BAPs from larvae experiencing epileptic seizures or drug-induced side
effects have substantially reduced complexity (entropy), similar to reduced LFP complexity
observed in Parkinson’s disease. To determine whether drugs that enhance BAP complexity
produces positive outcomes, we used light pulses to trigger seizures in a model of Dravet
syndrome, an intractable genetic epilepsy. The highest-ranked compounds identiﬁed by BAP
analysis exhibit far greater anti-seizure efﬁcacy and fewer side effects during subsequent in-
depth behavioral assessment. This high correlation with behavioral outcomes illustrates the
power of brain activity pattern-based screens and identiﬁes novel therapeutic candidates with
minimal side effects.
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Drugs used to treat brain disorders have typically beendiscovered empirically, often using animal behavioralmodels. This is due in large part to the complex and
highly interconnected nature of the brain, which presents sub-
stantial challenges for reductive cell culture assays and molecular
target-based screens. Indeed, many widely used neurotherapeutics
owe their efﬁcacy to action at multiple molecular targets, while
numerous promising compounds with potent activity in cell- or
target-based assays have limited clinical utility due to off-target
side effects1, 2. Thus, in vivo assays within the context of the intact
brain are essential for neuroactive drug screening.
However, similar to in vitro assays, behavioral readouts in
animal models often reduce complex neurological disorders to
simple metrics that do not completely reﬂect underlying deﬁcits
and off-target effects. Direct high-content readouts of neural
activity and brain activity patterns (BAPs) represent an attractive
alternative to behavior-based screens as they may more accurately
capture disease pathology, drug activity, and side effects. The
technical challenges of directly monitoring in vivo brain activity
in large-scale screens—combined with the high cost, low
throughput, and requirement for large quantities of compounds
—make the use of such advanced readouts impractical in rodent-
based models. Zebraﬁsh have recently emerged as an important
new vertebrate model for CNS diseases and drug screening that
may ultimately be able to meet these challenges3–5.
To demonstrate the power of chemical screening using brain
activity pattern analysis, we developed a high-throughput local
ﬁeld potential (LFP) recording platform capable of monitoring
brain activity simultaneously in many larvae over extended per-
iods of time using highly sensitive intra-animal microelectrodes.
LFPs reﬂect aggregate neural activity—including synaptic activity,
action potentials, calcium spikes, and afterpotentials—within the
local environment of the microelectrode, making them an
attractive tool for assessing systems-level processes6, 7. To detect
effects of drugs on brain activity patterns and brain disorders, we
developed algorithms that decompose LFP signals into indepen-
dent subcomponents. This allows us to monitor the in vivo
consequences of neuroactive compounds on brain activity pat-
terns in real time in order to quantify efﬁcacy and detect potential
side effects, as we conﬁrm using an in-depth 52-metric behavioral
assessment.
To validate our brain activity pattern-based approach, we
conducted a screen for antiepileptic drugs (AEDs) using a clini-
cally relevant model of epilepsy in zebraﬁsh. Zebraﬁsh have
already shown considerable promise for studying both acute
seizures and genetic epilepsies8. Larvae exposed to pentylenete-
trazole (PTZ) and other convulsants exhibit elevated locomotor
activity, seizure-like movements, and electrographic seizure
activity. PTZ-induced seizures can be monitored using automated
behavioral tracking systems and are suppressed by many clinically
effective AEDs9–12. Seizure-prone lines with mutations in
epilepsy-associated genes have also been characterized13–18. In
spite of the promise of zebraﬁsh seizure models, large-scale
screens using single-metric behavioral readouts often suffer from
a high false-positive rate—typically on the order of 75%—when
hits are retested using electrophysiology14, 19.
Our screen utilized two different zebraﬁsh lines harboring
independent mutations in the sodium channel gene SCN1A
(scn1lab in zebraﬁsh). SCN1A encodes the pore-forming alpha
subunit of the NaV1.1 sodium channel and is widely expressed
throughout the central nervous system. SCN1A mutations are
linked to variety of childhood epilepsies in humans20, 21. Dravet
syndrome (DS; also known as severe myoclonic epilepsy of
infancy), the most commonly reported pathology, is characterized
by frequent febrile seizures that appear during the ﬁrst year of life
and are often refractory to treatment by standard
anticonvulsants22. Over 1200 SCN1A mutations have been iden-
tiﬁed to date and the most severe clinical phenotypes correlate
with complete loss-of-function mutations or point mutations in
critical residues of the pore region21, 23. In addition to epilepsy,
SCN1A variants have been linked to autism and rare cases of
familial migraine, making it one of the most therapeutically
important sodium channel genes24, 25. We report for the ﬁrst time
that scn1lab loss-of-function mutations in zebraﬁsh give rise to
photosensitive seizure-like activity, consistent with photo-
sensitivity observed in many DS patients. This is the ﬁrst stable
genetic model of a photosensitive epilepsy that has been described
in zebraﬁsh or other common vertebrate model organisms, and
therefore represents an important new tool for investigating light-
triggered seizures and conducting in vivo drug screens.
Using light-triggered seizure-like locomotor activity as a simple
(single-metric) behavioral readout, we screened a diverse com-
pound collection to identify preliminary hits for in-depth char-
acterization using our LFP platform and algorithms. In addition
to spontaneous and light-triggered seizures, we observed that
scn1lab mutants exhibit a substantial decrease in LFP pattern
complexity during interictal periods. Brain activity patterns from
preliminary hits were therefore assessed using a multiparametric
approach: 1) seizure-like events were automatically detected using
an automated seizure detection algorithm and 2) LFP pattern
complexity was quantiﬁed using independent component analysis
(ICA). Based on these criteria, ~20% of the hits from the pre-
liminary simple behavioral screen proved highly effective at
reducing seizure frequency and restoring LFP pattern complexity.
To verify that our top-ranked LFP candidates correlate with
improved behavioral outcomes in scn1lab mutants, we carried out
an in-depth 56-parameter behavioral assessment of all pre-
liminary hits. Using both pathologic (ictal) and resting state
(interictal) behavioral metrics, we directly compared mutant and
wild-type behavioral proﬁles and evaluated compound effects on
both seizure-driven and normal behaviors. This approach reveals
a strong correlation between compounds that are effective based
on brain activity patterns and those that signiﬁcantly reduce
seizure-associated behaviors with minimal side effects. LFP pat-
tern analysis therefore provides a powerful tool for detecting and
eliminating the many false positives produced by simple beha-
vioral screens. Our multiparametric screening approach points
toward several promising new therapeutics for DS and other
epilepsies and illustrates the power of using brain activity pattern
analysis for CNS drug discovery.
Results
A genetic model of photosensitive epilepsy. The zebraﬁsh
scn1lab gene (previously known as double indemnity or didy)
encodes a voltage-gated sodium ion channel alpha subunit that is
orthologous to the mammalian SCN alpha subfamily comprising
SCN1A, SCN2A, SCN3A, and SCN9A26, 27. Mutations in SCN1A
—and to a lesser extent SCN2A, SCN3A, and SCN9A—are asso-
ciated with a variety of monogenic childhood epilepsies such as
DS in humans28–33. A presumptive loss-of-function mutation in
zebraﬁsh scn1lab (scn1labs552; Supplementary Fig. 1) causes
spontaneous electrographic seizure-like events and elevated
locomotor activity in larvae beginning at ~4 days post fertilization
(dpf). Based on previous studies, exposure of scn1labs552 larvae to
AEDs reveals a pharmacological proﬁle reminiscent of DS in
humans14.
Photosensitive seizures, which can be triggered by ﬂashing
stimuli, bright light, or strong contrast between darkness and
light, have been reported in 30–40% of patients with DS and are
often associated with more severe outcomes22, 34, 35. We therefore
sought to determine whether seizures can be triggered in scn1lab
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mutant larvae using simple visual stimuli. At 7 dpf, homozygous
mutants and age-matched sibling controls (a mixture of wild-type
and heterozygous larvae), were transferred to 96-well plates and
locomotor activity was assessed during a 10 min recording session
using an automated tracking platform capable of delivering a
range of computer-controlled light stimuli. We observed elevated
locomotor activity in mutants relative to siblings under both
constant light and constant dark conditions (Supplementary
Fig. 2a), consistent with previous reports14. We then stimulated
the larvae by administering either (1) a single brief (500 ms) light
pulse or (2) two light pulses separated by a 1 s interval. Light
stimuli were administered every 2 min in an otherwise dark
environment over the course of a 10 min recording session
(Fig. 1a). Mutants consistently exhibited short rapid bursts of
seizure-like locomotor activity commencing with the onset of the
light stimulus and persisting for ~5 s (Supplementary Fig. 2b,
Supplementary Movie 1). In contrast, wild-type siblings showed
almost no perceptible increase in locomotor activity in response
to light stimuli. In order to quantify light-triggered locomotion
we calculated mean swimming velocity over a 5 s interval
beginning with the onset of each light stimulus. Light-triggered
locomotor activity was signiﬁcantly higher in mutants than in
siblings and was markedly exacerbated by the dual pulse protocol
(Fig. 1b). The overall difference between mutants and sibling
controls was far more pronounced in response to light stimuli
than under either constant light or constant dark conditions, in
spite of the fact that the total analysis interval was reduced from
10min to only 20 s (i.e., four separate 5 s post-pulse intervals).
To verify that photosensitivity is a general feature of scn1lab
loss-of-function rather than a unique phenotype associated with
the scn1labs552 missense mutation, we tested a second previously
uncharacterized scn1labmutant generated as part of the Zebraﬁsh
Mutation Project36. The scn1labsa16474 allele introduces a C to A
mutation at position 1386 of the scn1lab open reading frame,
resulting in a premature stop codon at position 462 (p.Tyr462*)
(Supplementary Fig. 1). The mutation is located in the
intracellular loop between domains I and II and presumably
renders the ion channel nonfunctional. Homozygous mutant
scn1labsa16474 larvae exhibit the same morphological phenotypes
seen in scn1labs552 mutants37, including failure to inﬂate swim
bladders and a dark appearance due to dispersed melanosomes
(Supplementary Fig. 3). Mutant larvae fail to thrive and begin to
die at elevated rates relative to sibling controls beginning at
approximately 13 dpf (Supplementary Fig. 3). It remains unclear
if this is a secondary consequence of the swim bladder defect or a
more fundamental deﬁcit. Homozygous scn1labsa16474 mutants
exhibit the same seizure-like behavioral phenotypes seen with the
s552 allele, including elevated locomotor activity under constant
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Fig. 1 Light-induced seizures enable high-throughput screening in zebraﬁsh larvae with scn1lab mutations. a Schematic representation of light stimulus
parameters. Light stimuli are applied every 2min in an otherwise dark environment. Each stimulus consists of two consecutive 500ms light pulses
separated by 1 s of dark. b Box-and-whisker plots showing mean swimming velocity in scn1labs552 homozygous mutants (orange) and age-matched sibling
controls (blue). 12 siblings and 12 mutants are used per condition. For constant dark and constant light conditions, mean swimming velocities are calculated
over a full 10 min recording session. For light-triggered activity, velocities are calculated during 5 s intervals following the onset of each stimulus, resulting
in a total assay time of 20 s. Tops and bottoms of each box represent the 1st and 3rd quartiles. Whiskers are drawn from the ends of the interquartile
ranges (IQR) to the outermost data point that falls within ±1.5 times the IQR. The line in the middle of each box is the sample median. Statistical
signiﬁcance was determined by Welch’s t-test. c Representative local ﬁeld potential (LFP) recordings from the forebrains of scn1labs552 homozygous
mutant larvae and age-matched sibling controls at 7 dpf in response to light stimuli. Red arrows indicate the onset of the two 500ms light pulses. d
Breakdown of drug classes represented in the starting library (154 compounds) and following the behavioral screen (31 compounds; n= 8+ larvae, each
subjected to four independent light stimuli)
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light and constant dark conditions. Photosensitivity is also
present, with light pulses eliciting sudden rapid bursts of
seizure-like activity (Supplementary Fig. 2b, 4).
We next assessed both scn1labs552 and scn1labsa16474 mutants
for electrophysiological hallmarks of seizures. At 7 dpf, homo-
zygous mutant larvae and age-matched sibling controls were
embedded in low melting point agarose and forebrain LFPs were
recorded over a period of 4 h. As previously reported14,
scn1labs552 mutants exhibit spontaneous high-amplitude ictal
spikes when recorded under constant illumination. Spikes were
observed on average every 10± 1.5 min in mutant larvae and
were never detected in sibling controls. A similar pattern of
infrequent spontaneous ictal-like electrographic discharges was
observed in scn1labsa16474 mutants. To verify photosensitive
epilepsy, LFPs were monitored over the course of 10 min in
response to our light stimulus protocol. Mutant larvae exhibited a
distinctive LFP pattern in response to light stimuli, characterized
by multiple high-amplitude spikes commencing shortly after the
onset of each stimulus (Fig. 1c). In contrast, sibling controls from
both mutant lines showed a markedly different response pattern,
consisting of a single lower-amplitude spike coinciding with each
light pulse (Fig. 1c) and becoming progressively diminished in
amplitude with each subsequent presentation of the stimulus
(Supplementary Fig. 5). Taken together, these data show for the
ﬁrst time that light-triggered seizures are a general feature of
scn1lab mutations in zebraﬁsh and establish an important new
vertebrate genetic model for studying photosensitive epilepsies.
Preliminary AED screen by light-induced locomotor activity.
The ability to trigger seizures on demand in scn1lab mutant
zebraﬁsh using light stimuli provides a powerful tool for high-
throughput AED screening. To better understand the nature of
light-triggered seizures in scn1lab mutants and to explore the
range of potentially effective therapeutics, we assembled a library
consisting of 154 compounds covering speciﬁc neurotransmitter
pathways and drug classes (Fig. 1d, Supplementary Data 1).
Compounds chosen for screening included: (1) AEDs that are
commonly used to treat patients with DS, (2) compounds with
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Fig. 2 High-throughput local ﬁeld potential (LFP) recording platform. a Zebraﬁsh larvae are transferred to liquid 1.3% ultra-low gelling temperature agarose
(25 °C) and placed inside a 20mL syringe. The 20mL syringe is then inserted into a 60mL syringe ﬁlled with 2% low gelling temperature agarose (55 °C).
Syringes are capped with concentric 18-gauge and 16-gauge needles, respectively, allowing both agarose solutions to be simultaneously extruded into a
room temperature bath where they rapidly gel. Up to 50 larvae can be embedded in a single extrusion. b Diagram of a zebraﬁsh larvae embedded in an
ultra-low gelling temperature agarose core surrounded by a rigid agarose shell. Embedded larvae are loaded into glass capillaries prior to LFP recording. c
Schematic representation of the high-throughput LFP recording platform. Embedded larvae in glass capillaries are inserted into the platform in parallel
directly opposite an array of glass recording electrodes. The water-tight recording chamber bath is ﬁlled with zebraﬁsh embryo medium and the recording
electrodes are advanced into the larvae using miniaturized screws. Up to 16 larvae can be recorded simultaneously using a 16-channel preampliﬁer
connected to a low-power digital acquisition chip
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reported efﬁcacy in treating DS based on published human stu-
dies, (3) compounds with known or suspected anticonvulsant
activity in other types of epilepsy, including AEDs that are spe-
ciﬁcally contraindicated for use in DS due to interactions with the
SCN1A channel, (4) known neuroactive compounds with well-
characterized mechanisms of action targeting a wide spectrum of
neurotransmitter pathways and covering many common classes
of neuroactive drugs, and (5) compounds we identiﬁed in silico as
predicted binders to human SCN1A and SCN8A based on
similarity (p-value of 3.2 × 10−3) of the pocket adjacent to the
voltage sensing and pore domains to a mineralocorticoid receptor
pocket38, 39. Among the compounds identiﬁed in silico were
progesterone and mifepristone.
All compounds were initially assessed for locomotor impair-
ment and toxicity at a concentration of 100 μM. Those that
exhibited overt toxicity at 4-h post exposure based on reduced/
absent touch-evoked escape response were retested at lower
concentrations until a maximum tolerated dose was found.
Compound screening was carried out in 96-well plates and all
compounds were initially tested on groups of eight homozygous
mutant scn1labs552 larvae (1 per well). Prior to compound
application, an initial video recording was performed to establish
baseline locomotor activity for each test group. Light stimuli were
applied utilizing the dual-pulse parameters described previously
(Fig. 1a). Locomotor activity was recorded for 5 s beginning with
the onset of each light stimulus and a total of four stimuli were
administered over the course of 10 min. Immediately after the
baseline recording, compounds were applied directly to the wells
at the indicated concentration (Supplementary Data 1) and
additional recordings were performed beginning at 45 min, 2 h,
and 4 h post exposure. We evaluated the effect of all compounds
on abnormal light-triggered locomotor activity at each time point
by calculating the mean swimming velocity of each larva in
response to stimuli and normalizing to the baseline. Compounds
causing a statistically signiﬁcant reduction in activity (p< 0.05)
from baseline at one or more time points were veriﬁed by
rescreening on a larger pool of larvae.
We included a number of drugs with established clinical effects
on DS in our library to serve as positive controls and to assist in
selecting an optimal hit threshold for identifying compounds to
test in detailed follow-up screening. Controls included 11 drugs
that are either commonly used to treat DS or have shown efﬁcacy
in human studies (designated as “effective” in Supplementary
Table 1) and 6 AEDs that have been reported to worsen seizures
in patients with DS (designated “contraindicated”). A majority of
the clinically effective drugs reduced abnormal locomotor activity
by at least 50% at one or more of the post-exposure time points
(Supplementary Table 1). In contrast, all but one of the
contraindicated drugs failed to meet this criterion, indicating
that photosensitivity in scn1lab mutant zebraﬁsh may provide a
selective readout to identify compounds appropriate for treating
DS. We therefore chose a 50% reduction in abnormal light-
triggered locomotor activity as our assay threshold and deemed
all 31 compounds that met this criterion to be preliminary hits.
These compounds were veriﬁed by screening on the
scn1labsa16474 line, where most gave similar results (Supplemen-
tary Table 2). Our preliminary hits included compounds with a
wide variety of targets and appeared to be substantially enriched
for agonists and positive allosteric modulators of γ-aminobutyric
acid (GABA) receptors, particularly the GABAA receptor
(GABAAR; Fig. 1d, Supplementary Fig. 6).
Electrophysiology screen by high-throughput LFP recording.
We developed an LFP recording platform capable of simulta-
neously monitoring many zebraﬁsh larvae over extended periods
(4+ h) to rapidly assess the in vivo effect of all 31 preliminary hits
on brain activity patterns (Fig. 2). Our LFP setup consists of
parallel glass capillaries that hold agar-embedded zebraﬁsh larvae
along one side of a custom-fabricated recording chamber con-
taining the test compound of interest. On the opposite side of the
recording chamber, glass recording electrodes are precisely co-
centered with the agar-embedded larvae. These microelectrodes
are connected to a multi-channel preampliﬁer, which is con-
nected to an acquisition board. The recording electrodes are
advanced forward into the forebrains of larvae using miniaturized
screws. The electrical resistance and the average voltage on each
electrode is monitored as it penetrates the forebrain. Advance-
ment is halted when resistance decreases to 3MΩ and the average
noise is less than 0.2 mV RMS. In order to immobilize and pre-
cisely position non-anesthetized non-paralyzed zebraﬁsh larvae
within the glass capillaries for extended LFP recording sessions,
we devised a process through which 50+ larvae can be rapidly
embedded in a dual-layer agar cylinder (Fig. 2a, b; see Methods
for details). When coupled to a single 16-channel preampliﬁer,
our LFP platform allows us to obtain 4+ h recordings from up to
48 larvae in an ~12-h period. Considerably higher throughputs
can be achieved simply by using a preampliﬁer with additional
channels (e.g., 64- or 128-channels) and/or by reducing the
recording time. Standard electrophysiological analysis in zebraﬁsh
typically involves relatively short recordings on the order of 10
min rather than extended 4+ h recordings. In addition, custom
chips with large-scale integrated ampliﬁers can allow straight-
forward expansion of our method to industrial scale applications.
LFP seizure score. To assess the efﬁcacy of our preliminary hits
in reducing spontaneous seizures, we developed an automated
seizure detection algorithm based on methods previously used to
analyze EEG signals40 (see Methods for details) and used it to
deﬁne a seizure score. Our automated seizure detection algorithm
was trained to identify seizure-like events using LFP recordings
obtained from scn1lab mutants exposed to light stimuli as a
training data set. We then used the algorithm to measure spon-
taneous seizure frequency in compound-treated scn1lab mutants.
Baseline seizure frequency was ﬁrst determined for each larva
during a 30 min pre-exposure LFP recording. Following com-
pound administration, spontaneous seizure frequency was mea-
sured again between 130 and 240 min post exposure (see
Supplementary Table 3, seizure frequency, 240 min column). For
each compound (comp), a standardized seizure score ðScompÞ was
determined by ﬁrst normalizing the post-exposure seizure fre-
quency to the baseline frequency and then calculating
Scomp ¼ Fmut  Fcomp
 
=Fmut, where Fmut is the seizure frequency
in untreated (1% DMSO) scn1lab mutants and Fcomp is the fre-
quency in mutants treated with the compound of interest. The
seizure score therefore represents the overall improvement in
seizure frequency relative to untreated mutants (i.e., untreated
mutants will have a score of 0; wild-type sibling controls and
compounds with 100% efﬁcacy will have a score of 1.0; see
Supplementary Table 3, “seizure score” column). In addition, at
240 min post exposure all larvae were subjected to our standard
light-stimulus protocol in order to verify compound efﬁcacy on
light-triggered seizure-like activity (Supplementary Fig. 7).
LFP complexity score. In addition to the high-amplitude spikes
that characterize seizure-like events, we observed that interictal
LFP activity patterns in scn1lab mutants appear to be con-
siderably less complex and more stereotypic than in sibling
controls. We speculated that interictal pattern structure could
provide another metric to evaluate the efﬁcacy of neuroactive
compounds. In order to assess this aspect of the scn1lab
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phenotype, we utilized independent component analysis (ICA).
ICA is an unsupervised analysis method for separating multi-
variate signals into independent subcomponents and is widely
utilized for decomposition of EEG signals41. Typically, ICA is
used to perform blind spatial ﬁltering from multi-channel EEG
recordings; however, single-channel ICA can similarly be used to
perform blind temporal ﬁltering on data from a single sensor.
Single-channel ICA can accurately separate out important com-
ponents from a time series provided the sources are reasonably
spectrally disjoint, as has been shown to be the case for epileptic
EEG data42. Experimental studies suggest that the spatial reach of
the LFP signal is on the order of at least a few hundred micro-
meters6, a scale which encompasses a substantial portion of the
larval zebraﬁsh brain. Consequently, we assume that most of the
LFP signal is the summation of transmembrane currents arising
from many uncorrelated sources associated with multiple regions
and neuronal subtypes. Therefore, according to the central limit
theorem, the data will be approximately normally distributed.
ICA exploits the fact that the rest of the superposition of inde-
pendent non-Gaussian sources can be separated by optimizing
the fourth moment of the input43, 44. To assess signal complexity,
we ﬁrst apply our standard 10 min light-stimulus protocol
(Fig. 1a) beginning at 240 min post exposure and divide the
recording into multiple 30 s intervals using a sliding time window
with 80% overlap. Independent vectors are obtained as described
in Methods. These vectors are then used to decompose LFP
activity and calculate independent components (ICs) during a
subsequent 45 min unstimulated recording session.
When larvae are analyzed using our ICA approach, only a
small number of ICs tend to dominate LFP traces from untreated
scn1lab mutants (“low-complexity” LFPs), while traces from
sibling controls comprise a far greater variety of ICs (“complex”
LFPs; Fig. 3a). To quantify the efﬁcacy of compounds in
modulating LFP complexity, we developed an IC complexity
score based on ICA at 4-h post exposure. To calculate this metric,
we ﬁrst rank order ICs for each compound based on intensity and
then normalize all subsequent ICs to the ﬁrst IC (ICi/IC1).
Ineffective compounds and untreated mutants have low-
complexity LFP signals (dominated by a few strong ICs), so
normalized values drop off rapidly in the lower-ranked ICs. In
contrast, complex LFPs from sibling controls and from mutants
with “corrected” LFP patterns show less rapid attenuation of
lower-ranked ICs (Supplementary Fig. 8a). The ability of a
compound to restore LFP complexity in scn1lab mutants is
quantiﬁed by ﬁrst calculating two metrics: (1) Amut, the total area
separating the IC proﬁles of sibling controls and untreated
mutants (both in 1% DMSO; Supplementary Fig. 8b, yellow
region) and (2) Acomp, the total area separating the IC proﬁles of
sibling controls and compound-treated mutants (Supplementary
Table 3, total area column; speciﬁc examples shown in
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Supplementary Fig. 8c-h, yellow regions). For each compound, an
ICA score ICAcomp
 
is then calculated as follows:
ICAcomp ¼ Amut  Acomp
 
=Amut
As with the seizure score, the ICA score reﬂects the overall
improvement in LFP pattern complexity relative to untreated
mutants (untreated mutants = 0; sibling controls=1.0; Supple-
mentary Table 3, ICA score).
Seizure scores and ICA scores allow us to evaluate the efﬁcacy
of each compound on two scales: desirable compounds should
both reduce the number of seizure-like events and restore the
interictal LFP pattern to a more wild-type state. These two
readouts can be combined to obtain a single composite LFP score,
which provides a multiparametric indicator of overall compound
efﬁcacy. This is done by using ICA and seizure scores specify a
single XY coordinate on a scatterplot for each compound. The
composite LFP score is then calculated as follows:
Distmut  Distcomp
 
=Distmut, where Distmut is the Euclidean
distance between sibling controls and untreated scn1lab mutants
and Distcomp is the distance between sibling controls and
compound-treated mutants (Supplementary Fig. 9). As with
ICA and seizure scores, the closer the composite LFP score is to
1.0 the more effective the compound is at normalizing mutant
brain activity patterns. Based on this score, 6 of our 31
preliminary hits are highly effective at restoring LFP recordings
to a more wild-type state (Fig. 3b, Supplementary Table 3;
progesterone, mifepristone, pargyline, promethazine, ﬂuoxetine,
and allopregnanolone). Pyrilamine may also show some efﬁcacy.
Validation of LFP analysis by deep behavioral phenotyping. To
conﬁrm that brain activity pattern analysis identiﬁes compounds
with superior efﬁcacy and fewer side effects, we carried out an in-
depth behavioral assessment of all 31 preliminary hits using
multiple independent metrics instead of a single-behavioral out-
come (i.e., mean swimming velocity). In order to develop more
sophisticated behavioral readouts, we used two complementary
approaches. We ﬁrst identiﬁed additional behavioral metrics that
can be reliably detected and quantiﬁed from high-resolution
video recordings of zebraﬁsh larvae in multiwell plates (Fig. 4a).
Metrics include mean swimming velocity (Vm; pixels s−1), max-
imum swimming velocity (Vmax; pixels s−1), mean change in tail
angle (dTBm; degrees s−1), maximum change in tail angle
(dTBmax; degrees s−1) mean tail bending angle (TBm; degrees),
maximum tail bending angle (TBmax; degrees), time spent at rest
(RT; seconds), and number of locomotor bursts (LBm; deﬁned as
a transition from V=0 to V> 0). We then broke each behavioral
metric down into temporal windows that were deﬁned relative to
the onset of the seizure-inducing light stimulus: (1) ﬁrst light
pulse (0–0.5 s), (2) inter-pulse interval (0.5–1.5 s), (3) second light
pulse (1.5–2 s), (4) early post-pulse 1 (2–3 s), (5) early post-pulse
2 (3–27.5 s), (6) early interictal (27.5–65 s), and (7) late-interictal
(65–105 s) (Fig. 4b).
To verify that in-depth behavioral metrics can reliably
distinguish between mutants and siblings, we examined each
metric using a large number (n = 40+) of DMSO-treated controls
and our standard light stimulus parameters (Fig. 1a). Although
individual behavioral metrics from single larvae show consider-
able variation—presumably due to the complex and stochastic
nature of the neurological processes underlying photosensitivity
and locomotor response—average metrics derived from multiple
larvae exposed to multiple stimuli exhibit clear and robust
patterns (Supplementary Fig. 10). As expected, most behavioral
metrics in mutants undergo a dramatic change from baseline
almost immediately after the onset of the light stimulus (Fig. 4b).
Not surprisingly, wild-type siblings also initiate locomotor
responses when subjected to light stimuli, although these differ
substantially from mutants in both magnitude and overall
temporal progression.
We rescreened all 31 preliminary hits at 4-h post exposure using
deep behavioral phenotyping and the same assay parameters as the
preliminary screen (Fig. 1a). An average activity proﬁle was created
for each compound by combining all recorded light stimulus
events from all larvae (n = 40+) and normalizing all features. The
result is a unique behavioral ﬁngerprint made up of 56 values
(eight behavioral metrics broken down into seven temporal
windows) for each compound. Although behavioral ﬁngerprints
from untreated scn1lab mutants and sibling controls differ
dramatically, the strongest differences are observed during the
temporal windows encompassing the light stimulus itself and the
subsequent seizure resolution period (from t = 0 s through t = 27.5
s). Behavioral metrics show fewer differences during the early and
late interictal periods (t = 27.5–105 s), indicating that the snc1lab
mutation does not substantially alter the mean behavioral proﬁle in
the absence of induced seizures. This becomes clear when all
compounds are ranked based on Euclidean distance from siblings
using only metrics from interictal temporal windows 6 and 7
(Fig. 4c). In this analysis, 19 out of 31 preliminary hits fall further
from the wild-type end of the spectrum than untreated mutants,
suggesting they alter relatively normal interictal behaviors and may
have undesirable side effects that could give rise to false positives
(e.g., sedation) or indicate other off-target concerns. We therefore
ﬂagged compounds ranked in the upper quartile of the interictal
behavioral spectrum (i.e., those furthest from siblings) as abnormal.
We then assessed behavioral ﬁngerprints in detail by performing
hierarchical clustering (MATLAB clustergram function, Math-
Works, Natick, MA) based on Euclidean distance using Ward’s
linkage algorithm45. On the resultant dendrogram, siblings and
untreated mutants are located on highly divergent clusters
(designated “Cluster-WT” and “Cluster-M”, respectively), indicat-
ing that the behavioral proﬁles of these two groups are strikingly
different (Fig. 4d). The most effective compounds based on
composite LFP scores all produce behavioral ﬁngerprints that
localize to Cluster-WT, conﬁrming that brain activity pattern
(BAP) analysis is a powerful tool for accurately assessing in vivo
efﬁcacy (Fig. 4d; LFP hits are indicated by a check mark). Several
compounds with highly abnormal interictal behavioral proﬁles also
localize to Cluster-WT, suggesting that behavioral side effects can
indeed mimic AED activity and are likely responsible for many
false positives in locomotor activity screens. Importantly, all of our
top hits based on BAP analysis cluster with sibling controls in deep
behavioral phenotyping and only one (allopregnanolone) exhibits
abnormal interictal behavior, conﬁrming that our approach, unlike
screens based on simple locomotor metrics, reliably eliminates false
positives while simultaneously avoiding false negatives (Fig. 5).
Additionally, we observed that most of the structurally and
mechanistically related benzodiazepines (5/6; 83%) co-localize to a
single subcluster of the dendrogram, suggesting that behavioral
ﬁngerprints may prove useful for sorting neuroactive compounds
into biologically meaningful groups in addition to assessing
therapeutic endpoints (Fig. 4d). The benzodiazepine subcluster is
located on Cluster-M along with untreated mutants, in agreement
with our LPF data showing that benzodiazepines, at least at the
concentrations used in our screen, are not highly effective at
restoring brain activity to a more wild-type state.
Discussion
Epilepsy impacts approximately 65 million people worldwide,
with an annual incidence in the United States and in Europe of
~55 per 100,000. One in twenty-six people will develop epilepsy
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during their lifetime46. Although existing AEDs control seizures
effectively in many patients, 30–40% remain refractory to treat-
ment and develop chronic epilepsy. Even those who achieve
adequate seizure control frequently experience undesirable
cognitive and behavioral side effects47. For these reasons, the
discovery of new therapeutics and alternative druggable targets
remains a high priority. For over 60 years most in vivo AED
screening has relied on behavioral readouts in rodent models.
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inducing light stimulus: (1) ﬁrst light pulse (0–0.5 s), (2) inter-pulse interval (0.5–1.5 s), (3) second light pulse (1.5–2 s), (4) early post-pulse 1 (2–3 s), (5)
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points (n= 10+ larvae, each subjected to four independent light stimuli) per metric over all seven temporal intervals. Representative examples are shown
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controls (blue). c Behavioral ﬁngerprints ranked based on Euclidean distance from sibling controls (green) during interictal periods (temporal windows 6
and 7). Compounds in the upper quartile (furthest from siblings) are presumed to have adverse side-effects on resting state behavior and are designated
abnormal (orange text). Mutants are indicated in red text; hits based on LFP analysis are indicated by check marks. d A 56-component behavioral
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outcomes. Cluster-M contains compounds with behavioral proﬁles similar to untreated mutants (red text) and Cluster-WT contains compounds with
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Unfortunately, rodents are poorly suited for large compound
screens and behavioral readouts typically reduce complex neu-
rological events to a few easily observed parameters. In this
report, we show for the ﬁrst time that direct analysis of brain
activity patterns can be incorporated into a seizure model that is
suitable for large-scale, high-throughput drug screening.
Although we demonstrate our approach using a genetic model of
epilepsy, the overall screening paradigm we propose is applicable
to any disorder that alters normal brain activity patterns (BAPs).
Recently, multichannel platforms for simultaneous electro-
physiological monitoring of multiple zebraﬁsh larvae have been
described48. However, unlike our high-throughput LFP platform,
in which microelectrodes are inserted directly into the brain,
these approaches detect activity from the exterior of the animals
(as in EEG) resulting in smaller amplitude signals and an overall
reduction in assay sensitivity. Their suitability for large-scale
screening and novel drug discovery remains to be demonstrated.
The superior sensitivity of our platform means that are able to
decompose and analyze brain activity patterns during interictal
periods in addition to detecting more obvious high-amplitude
seizure-like events. This ﬂexibility allows us to evaluate com-
pounds based on two metrics: overall seizure frequency and
interictal LFP signal complexity. Our results represent the ﬁrst
time that a high-throughput multichannel electrophysiology
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platform has been tested on more than a handful of compounds
and cross-validated using in-depth behavioral assays.
Our approach to brain activity pattern analysis in the zebraﬁsh
scn1lab model is interestingly reminiscent of the recent work on
adaptive deep brain stimulation. In Parkinson’s disease, exag-
gerated beta frequency oscillations and synchrony in the sub-
thalamic nucleus correlate with reduced LFP complexity, which is
a highly predictive metric of motor impairment in patients49.
Application of deep brain stimulation during pathological beta
oscillations reduces abnormal activity patterns and synchrony,
and leads to clinical improvement50. Exactly why LFP complexity
in Parkinson’s disease is linked to impairment remains to be
determined, but signal complexity may be an indication of the
information carrying or processing capability of the brain.
Based on both LFP pattern analysis and in-depth behavioral
proﬁling, 6 of our 31 preliminary hits show clear efﬁcacy in
controlling seizure-like activity in scn1lab mutants, indicating a
false-positive rate on the order of ~80% for simple behavioral
screens. Previous behavior-based screens for AEDs have reported
similar false-positive rates when preliminary hits are validated14, 19.
This large number of false positives suggests that behavioral read-
outs based on single parameters (like mean swimming velocity) are
highly susceptible to off-target effects that mimic desired ther-
apeutic outcomes. Drugs with anesthetic, sedative, or related
properties that suppress locomotor activity without correcting
underlying pathologies are one likely source of false positives.
Consistent with this, among our preliminary behavioral hits that
failed in subsequent LFP screening were two local anesthetics
(prilocaine and mepivacaine; both sodium channel blockers) and
a number of compounds with well-documented sedative effects,
including eight GABAA receptor positive allosteric modulators
(Supplementary Table 2). Although GABAA receptor modulators,
including benzodiazepines, are used to manage diverse types of
epilepsies including DS, their therapeutic utility is often limited
because of well-known side effects including sedation and cog-
nitive impairment51. Much of the activity seen for benzodiaze-
pines in our preliminary screen appears to be due to sedation
rather than antiepileptic activity, since none were particularly
effective in either LFP assays (Supplementary Table 3) or deep
behavioral phenotyping (Fig. 4d).
Although both diazepam (a benzodiazepine) and stiripentol (a
structurally novel modulator of the GABAA receptor) failed to
improve brain activity patterns in our hands, previous publica-
tions suggest that they are capable of reducing spontaneous
electrographic seizures in scn1lab mutant zebraﬁsh. However,
both compounds have only been evaluated at extremely high
concentrations (1 mM) in zebraﬁsh14. In contrast, we screened
them at substantially lower levels (10–20 μM) based on results
from our preliminary toxicity assessment, which revealed a
noticeable reduction in touch response at concentrations as low
as 100 μM. This suggests that higher concentrations may produce
signiﬁcant side effects in addition to anti-seizure activity. To
determine whether we could replicate published results using our
platform and algorithms, we retested both diazepam and stir-
ipentol at 100 and 200 μM. Under these conditions, we do indeed
observe a signiﬁcant reduction in the number of spontaneous
seizure-like events in mutant larvae, however this is not accom-
panied by a corresponding improvement in the ICA complexity
score (Supplementary Table 4, Supplementary Fig. 9). Addition-
ally, when wild-type sibling controls are exposed to diazepam and
stiripentol at these higher concentrations, we observe both a
dramatic drop in their ICA complexity scores as well as sig-
niﬁcant behavioral side effects (Supplementary Table 4; Supple-
mentary Fig. 11). Based on these data, we conclude that the
antiepileptic activity of diazepam and stiripentol in scn1lab
mutant larvae occurs only at concentrations that cause
considerable off-target side effects. In the case of stiripentol,
which has received orphan drug status for the treatment of DS, it
should be noted that it is often combined with other AEDs
clinically. At least some of its therapeutic activity is thought to
arise from inhibition of their metabolism rather than from its
own activity at the GABAA receptor52. Such combinatorial
activity is not studied in our screen, which only uses individual
compounds.
The top hits from our LFP screen represent a remarkably
diverse group of compounds. They include a ﬁrst-generation
antihistamine (promethazine), two pregnane steroids (proges-
terone and allopregnanolone), a selective serotonin reuptake
inhibitor (ﬂuoxetine), a selective monoamine oxidase-B inhibitor
(pargyline), and a synthetic C19 norsteroid (mifepristone). A
second antihistamine (pyrilamine, also known as mepyramine)
shows marginal activity. Signiﬁcantly, all ﬁve of the best com-
pounds based on deep behavioral phenotyping are included
among our top six LFP hits (Fig. 4d). This suggests a remarkably
robust correlation between brain activity patterns and behavioral
outcomes (Fig. 5).
Further validating our ﬁndings, one of our top hits (ﬂuoxetine;
a selective serotonin reuptake inhibitor), has recently been
reported to cause a marked reduction in seizures in an adult
woman with DS53. Additionally, recent studies using the zebraﬁsh
scn1lab model have shown that a number of other serotonergic
modulators—including lorcaserin, trazodone, GR 46611, and
TCB-2—are effective in suppressing seizures54, 55. Although these
compounds were not included in our screen, their activity is
consistent with what we observe for the serotonergic modulator
ﬂuoxetine. In particular, much like ﬂuoxetine, trazodone’s anti-
depressant activity is thought to arise from inhibition of serotonin
reuptake56. Somewhat surprisingly, we did not observe signiﬁcant
efﬁcacy for either dexfenﬂuramine or clemizole (both putative
serotonin modulators) in our LFP screen in spite of the fact that
both have been identiﬁed in previous scn1lab screens19, 57 and
fenﬂuramine is used clinically for treating DS58–61. As with dia-
zepam and stiripentol, these discrepancies most likely stem from
differences in dosing. We tested dexfenﬂuramine at 100 μM over
the course of 4 h, whereas previous studies in zebraﬁsh have used
either higher concentrations (500 μM)19 or longer exposure times
(24 h)57, 62. Similarly, we screened clemizole at a concentration of
10 μM based on our preliminary toxicity assessment, whereas
previous studies have only reported anti-seizure activity at 300+
μM (for a 30-min exposure) and at 100 μM (for a 90-min
exposure)55. As with diazepam and stiripentol, retesting clemizole
at higher concentrations reduces the number of spontaneous
seizures but fails to improve the ICA complexity score (Supple-
mentary Table 4).
One potentially interesting class of compounds picked up by
our screen is a structurally related group of C21 (pregnane)
steroids. Our chemical library contained three members of this
class (allopregnanolone, ganaxolone, and progesterone), all of
which were among the top hits in our preliminary behavioral
screen. Progesterone subsequently tested positive for anti-seizure
activity based on both its composite LFP score and deep beha-
vioral phenotyping, while allopregnanalone (3α-hydroxy-5α-
pregnan-20-one) appeared to be highly effective based on its LFP
score but showed some behavioral side effects. Among our top
hits, allopregnanolone was the most effective at improving the
seizure component of the LFP score (seizure score = 0.93) but the
least effective at improving the ICA complexity component (ICA
score = 0.69; Supplementary Table 3). Interestingly, although
allopregnanolone’s effect on interical metrics (temporal windows
6 and 7; Fig. 4c) caused us to ﬂag it as abnormal in deep beha-
vioral phenotyping, it still clustered with sibling controls (Fig. 4d)
due to its efﬁcacy at reducing abnormal light-triggered ictal
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behaviors (temporal windows 1–5). This outcome—strong anti-
seizure activity in combination with abnormal locomotor activity
and a relatively poor ICA score—is reminiscent of what we
observed with high concentrations of diazepam and stiripentol
(Supplementary Table 4). Taken together, these data suggest
allopregnanolone many possess both anti-seizure activity and off-
target side effects.
Allopregnanolone is an endogenous pregnane neurosteroid
that is synthesized in vivo by 5α-reduction of progesterone63, 64.
It has been shown to exhibit potent anticonvulsant effects in
diverse animal models63 and clinically in patients with super-
refractory status epilepticus65 and appears to be less subject to
anticonvulsant tolerance than benzodiazepines66, 67. Unlike pro-
gesterone, allopregnanolone is not believed to have activity at
nuclear steroid hormone receptors64, 68. Conversely, progesterone
itself is not a GABAA receptor modulator, but it can be meta-
bolized to allopregnanolone and other related compounds. The
anti-seizure effects of progesterone may therefore occur through
its conversion to allopregnanolone, as has been shown in other
animal models69. However, the time course of this effect is
remarkably rapid based on our data, with light-induced seizure-
like locomotor activity dropping to 31% of baseline within 45 min
of application (Supplementary Data 1) and spontaneous LFP-
detected seizure frequency decreasing to 27% of baseline in a
comparable timeframe (Supplementary Table 3, seizure fre-
quency, 45 min column). Based on our results, allopregnanolone
and compounds with related pregnane skeletons warrant further
investigation as therapeutics for DS.
Methods
Fish maintenance. All procedures on live animals were approved by the Massa-
chusetts Institute of Technology Committee on Animal Care. The scn1labs552 line
(also known as double indemnity or didy) has been described previously14. The
scn1labsa16474 line was obtained from the Zebraﬁsh International Resource Center
(Eugene, OR; ZIRC catalog # ZL9291.15). Both lines were outcrossed to the wild
type TAB-14 line (ZIRC catalog #ZL1438) prior to analysis. Adult zebraﬁsh were
maintained under standard laboratory conditions and larvae were staged as
described70. Fertilized eggs were generated by crossing heterozygous adults and
raised on a 12 h light/12 h dark cycle at 28 °C in E3 medium (5 mM NaCl, 0.17 mM
KCl, 0.33 mM CaCl2, 0.33 mM MgSO4, pH 7.2).
Compound screening. At 7 dpf, homozygous mutant larvae were identiﬁed based
on the presence of dispersed melanosomes, which give rise to a darkly pigmented
phenotype37, and single larvae were distributed into individual wells of ﬂat-
bottomed 96-well microplates (MultiScreen 96-well Transport Receiver Plate,
Millipore, Billerica, MA) in a volume of 100 μL of E3 medium per well. Microplates
with larvae were placed into the enclosed, light-controlled imaging chamber of our
automated video tracking system (described in detail below) and allowed to adapt
to the dark environment for 20 min. Following adaptation, but prior to the
application of test compounds, locomotor activity was assessed in response to light
stimuli to determine the baseline activity level. Each light stimulus was delivered by
a computer controlled LED and consisted of two 500 ms light pulses separated by 1
s of darkness. Locomotor activity was calculated based on response to four light
stimuli, each separated by 2 min of darkness (Fig. 1a).
Stocks of all test compounds were prepared at 10 mM in 100% dimethyl
sulfoxide (DMSO), aliquoted, and stored at −20 °C (see Supplementary Data 1 for
CAS number, supplier, and catalog number). On the day of the experiment, 2×
working stocks of each compound were prepared in E3 medium and the DMSO
concentration was adjusted to 2%. A volume of 100 μL of the 2× working stock was
added to each well immediately after acquisition of the baseline locomotor
recording (n = 8–10 larvae per compound), resulting in the indicated screening
concentrations (Supplementary Data 1) and a ﬁnal DMSO concentration of 1%.
Following compound addition, additional locomotor activity recordings were
acquired at beginning at 45- min, 2 h, and 4 h post exposure using the same light
stimuli parameters that were used for the baseline recordings (Fig. 1a).
For preliminary compound screening, the mean swimming velocity of each
larva at each assay time point (baseline, 45 min, 2 h, and 4 h post exposure) was
calculated based on total locomotor activity recorded during the 5 s intervals
following each of the four light stimuli. All post-exposure velocities were
normalized to baseline activity level for each treatment group and a correction
factor was applied to compensate for a slight upward drift in locomotor activity
that was consistently observed in DMSO-only controls at all post-exposure time
points. For any given post-exposure recording session, this correction factor was
equal to the mean velocity of the untreated (i.e., DMSO-only) control group during
the baseline recording session divided by the mean velocity of the same untreated
control group during the post-exposure recording session.
Automated video tracking system. Locomotor activity was recorded using a
custom-built video tracking system comprising a monochrome CCD camera
(Manta G-033; Allied, Exton, PA) ﬁtted with a motorized close-focusing macro
video lens (Zoom 7000 lens system, Navitar, Rochester, NY), a near-IR longpass
ﬁlter (LP800-52, MidOpt, Palatine, IL), a motorized stage (H101A; Prior, Rockland,
MA) and a IR, whitelight LED illuminator (BX 06 06 WHI/IR, Advance illumi-
nation, Rochester, VT). The system was surrounded by a custom-made light-tight
optical table enclosure (1 m × 1m × 0.4 m) and mounted on an optical breadboard
base (Newport Corporation, Irvine, CA). The IR/LED illumination was controlled
by an Arduino Mega 2560 microcontroller board (digital output range from 0.0 to
5.0 V; Adafruit Industries, New York, NY).
High-throughput LFP recording platform. The recording chamber of the high-
throughput LFP platform is made of two 1 × 2 × 8 cm aluminum bars placed in
parallel using two 4 cm screws, directly jointing two aluminum bars. Glass capil-
laries (1.1 mm inner diameter; 1.5 mm outer diameter; BF150-110, Sutter Instru-
ment Company, Novato, CA) serve to hold agar-embedded zebraﬁsh larvae. These
are arranged in a parallel conﬁguration and inserted through equally spaced
mounting holes drilled along one side of the recording chamber. In order to seal
the recording chamber, each mounting hole is equipped with a water tight 1.2 mm
gasket that ﬁts tightly around each capillary. On the opposite side of the recording
chamber, glass recording electrodes are inserted through a second series of
mounting holes precisely co-centered with those holding the glass capillaries.
Recording electrodes are made by pulling a 1 mm outer diameter capillary (BF100-
78-10, Sutter Instrument Company), which is ﬁlled with 1M chloride solution. The
electrodes are held using a 1 mm water tight gasket to fully waterproof the whole
chamber. A Ag/Cl wire (64–1320, Harvard Apparatus, Holliston, MA) is then
placed inside each electrode, each wire is connected to a 16-channel preampliﬁer
(RHD2216, Intan Technologies, Los Angeles, CA), and the preampliﬁer is con-
nected to a low-power digital acquisition chip (RHD2000, Intan Technologies;
Fig. 2c). The signal from acquisition board is recorded using Intan MATLAB GUI
software (MATLAB 13, Mathworks, Natick, MA). The data are then denoized and
analyzed to obtain independent components using custom MATLAB code as
described below.
Dual-layer agarose embedding. In order to immobilize and precisely position
zebraﬁsh within the glass capillaries for extended LFP recording sessions, we
devised a process through which larvae can be embedded in a cylinder of 1.3%
ultra-low gelling temperature agarose (which solidiﬁes at 25 °C; A2576, Sigma)
surrounded by shell of 2% low gelling temperature agarose (which solidiﬁes at 55 °
C; A0701, Sigma; Fig. 2a, b). Unlike most immobilization protocols used for LFP
recording in zebraﬁsh larvae, ours does not require any paralytic agent. The ultra-
low gelling temperature core allows larvae to be safely added to the agarose while in
a liquid state without being exposed to excessive temperatures. The more rigid low
gelling temperature agar shell strengthens and supports the inner core, allowing it
to be inserted into the glass capillary and ensuring that the larvae are fully
immobilized. Embedding is accomplished by ﬁrst transferring larvae into a solution
of liquid 1.3% ultra-low gelling temperature agarose, which is then poured into a
20 mL syringe. The 20 mL syringe is then inserted into a 60 mL syringe ﬁlled with
2% low gelling temperature agarose. The 20 mL syringe is capped with an 18-gauge
blunt tip dispensing needle and the 60 mL syringe is capped with a 16-gauge
needle. We then simultaneously extrude both agarose solutions into a room tem-
perature bath containing E3 medium (Fig. 2a). Following embedding, larvae are
transferred to the glass capillaries of the LFP recording platform and recording
electrodes are advanced into the forebrains using miniaturized screws. The elec-
trical resistance and the average voltage on each electrode is monitored as it
penetrates the forebrain. Advancement is halted when resistance decreases to 3 MΩ
and the average noise is <0.2 mV RMS. If resistance deviates from the initial value
by more than 50% over the course of the recording, the sample is excluded from
further analysis since it indicates the electrode may have shifted position or become
damaged. Unless otherwise noted, all electrophysiological screening was done using
5–11 larvae per compound/condition (with an average of 8.3 per condition).
Automated seizure detection. Automated seizure detection is accomplished using
XGBoost, an open-source machine learning system for gradient tree boosting71, to
classify electrophysiological signals into seizure and non-seizure classes using
higher-order statistical moments as features. Similar approaches using higher order
statistics have been used successfully to classify EEG signals40. Training and test
data sets for building and evaluating our gradient boosting algorithm are generated
using 10 min LFP recordings from 20 scn1lab mutants, which are subjected to our
standard light-stimulus protocol in order to trigger seizures on demand at known
time points (Fig. 1a). The ampliﬁed signal is ﬁltered using a ﬁrst-order 3 kHz
lowpass anti-aliasing ﬁlter and sampled at a rate of 3k samples per second. The
time series signal is then ﬁltered using a second-order Butterworth bandpass 0.5 Hz
to 1 kHz ﬁlter and divided into 30 s windows with 20 s of overlap between each
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consecutive window. Windows corresponding to light stimuli are coded as “seizure”
intervals; all others are coded as “non-seizure” intervals. For each 30 s interval, we
extract ﬁve statistical metrics from the time-varying amplitude of the signal: mean,
variance, skewness, kurtosis, and fourth power mean. The feature vector for each
30 s window consists of 15 total features: 5 features from the window itself and well
as 5 from each of the two preceding partially overlapping windows. We use the
features from 80% of the windows as a training data set for our gradient boosting
algorithm. We use 20 decision trees each with a maximum depth of 5 to accom-
plish this. The remaining 20% of the windows are used as a validation data set to
evaluate the performance of the trained algorithm. Similar to the previous work
using higher-order statistics to detect seizures40, our algorithm gives very high
seizure detection accuracy (~95%).
Independent component analysis. We use an automated single-channel ICA
algorithm previously described42 to ﬁnd independent components corresponding
to separate sources before and after seizure onset. We start with LFP recordings
performed under our standard light stimulus parameters (Fig. 1a). The ampliﬁed
signal is ﬁltered as described above and divided into 30 s vectors with 80% overlap
between each consecutive vector. The vectors are arranged into a data matrix X,
which is a superposition of independent vectors. Assuming W ¼ E XXt½  is the
autocorrelation matrix, the correlation between samples is removed to generate a
white spectrum random process as follows:
Ω ¼ W1=2XW1=2
Now consider Ω ¼Pαiβi , where βi is the independent vector and αi is the
scaling factor. The ﬁrst independent vector is obtained by optimizing the fourth
moment of time series72:
minβ1 :jjβ1 jj¼1
X
βT1 ΩΩ
  4
The residual is then calculated by subtracting the ﬁrst component signal using
Ωi¼ Ωi1  βi1nΩi1
 
βi1, where Ω1¼ Ω.The residual is used to calculate the
next independent vector as:
minβi :jjβi jj¼1
X
βTi Ωi Ω
  4
The ith independent component (ICi) of the signal over time is calculated by
ICiðtÞ ¼ βinΩðtÞ, where βi is the solution of the optimization and where ΩðiÞ is the
ith 30 s vector and Ω is the average of ΩðtÞ.
Automated deep behavioral phenotyping. Segmentation of the microplate wells
is done with a snake algorithm73. The known rough position of the microwell plate
is used as the initial guess for the snake. Larvae are tracked using a background
subtraction approach to extract moving features. An empty background image is
ﬁrst created by taking the maximum of all frames in the video stream. This
background image is then subtracted from each frame in the recording session.
Larvae tails are enhanced with a Gabor ﬁlter74, 75 and a threshold is used to
generate a binary image of all larvae. The position of the head is found by detecting
the local maxima of the low-pass ﬁltered foreground image76. To speed up the
algorithm, we perform a correlation between the detected object in each well with
the object in the previous frame. If the correlation is above a predetermined
threshold the larva is considered to be stationary and the result from previous
frame is used. A skeletonization is done on the binary object followed by a distance
transform from the head constrained by the binary skeleton. The point furthest
away from the head is considered to be the tip of the tail. We next ﬁnd the
centerline of the larval body and tail. The shortest path is calculated from the head
to the tip of the tail with the Gabor ﬁltered enhanced image as weights using the
MATLAB Accurate Fast Marching plugin77, 78. Five equally spaced vertex points
are positioned along the detected centerline (shortest path) from the head to the tail
tip.
We use the ﬁve centerline points to calculate several features. All features are
broken down into temporal windows as described in the text and both mean and
maximum feature values are calculated for every window. The mean swimming
velocity (Vm; pixels s−1) and maximum swimming velocity (Vmax; pixels s−1) are
calculated based on the distance traveled by the head of the larva. The tail angle is
calculated for each vertex point and the absolute values of all points are summed
together. These values are used to calculate the mean tail bending angle (TBm;
degrees) and the maximum tail bending angle (TBmax; degrees). Mean change in
tail angle (dTBm; degrees s−1) and maximum change in tail angle (dTBmax; degrees
s−1) are based on the sum of change in tail angle for each vertex point. When there
is no change in tail angle, a ﬁsh is considered to be at rest and these frames are used
to calculate time spent at rest (RT; seconds). The last feature we calculate is the
number of locomotor bursts (LBm;). This metric is based on the number of
transitions from rest to active tail movement that occur within a given temporal
window. All feature metrics are combined to create a behavioral ﬁngerprint for
each compound. Fingerprints are automatically assessed using MATLAB’s
clustergram function (MathWorks, Natick, MA) to perform hierarchical clustering
based on Euclidean distance using Ward’s linkage algorithm45 and to generate heat
maps.
Code availability. Core source code for LFP analysis, seizure detection, and basic
video tracking of larvae is available online from GitHub (https://github.com/
rezaie99/NC-17-6337).
Data availability.. Any data sets generated and analyzed during the current study
that are not contained within the manuscript are available from the corresponding
author on reasonable request.
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